FDA Clears Golimumab Biosimilars - Summary - MDSpire

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

  • By

  • Kathryn Wighton

  • May 18, 2026

  • 2 min

Share

Objective:

To report on the FDA's approval of Immgolis and Immgolis Intri as interchangeable biosimilars to Simponi and Simponi Aria for rheumatoid arthritis and ulcerative colitis.

Key Findings:
  • Immgolis and Immgolis Intri are the first interchangeable biosimilars for golimumab.
  • Pharmacokinetic analyses showed similar exposure and immunogenicity profiles.
  • Interchangeable biosimilars allow for pharmacy-level substitution under FDA standards.
Interpretation:

The approval of these biosimilars is expected to provide lower-cost treatment options while maintaining comparable clinical outcomes to the reference biologics.

Limitations:
  • The safety profile includes risks of serious infections and malignancies.
  • Common adverse events reported are similar to those of the reference products.
Conclusion:

The introduction of Immgolis and Immgolis Intri represents a significant advancement in treatment options for rheumatoid arthritis and ulcerative colitis, potentially improving access to care.

Original Source(s)

FDA Clears Golimumab Biosimilars

  • by Kathryn Wighton

  • May 18, 2026

Related Content

Sex Differences Seen in Immune Cells

Single-cell analysis identified sex-biased immune-cell composition, gene expression, and genetic regulation in unstimulated blood immune cells

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

Tofacitinib vs Adalimumab Findings Require Caution in RA

Meta-analysis favored tofacitinib for some rheumatoid arthritis outcomes, but high heterogeneity, dose-dependent effects, and JAK inhibitor safety concerns complicate interpretation.